Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-02-24
    E.g., 2018-02-24

Articles

19185 items
12:00 AM, May 03, 1993  |  BioCentury | Politics, Policy & Law

30-day mortality rates; 30-day mortality or stroke

30-day mortality rates; 30-day mortality or stroke streptokinase (SK) + subcutanous heparin 7.2% SK + intravenous heparin 7.4% Pooled SK 7.3% tPA + SK + intravenous heparin 7.0% tPA + intravenous heparin 6.3% Relative...
12:00 AM, Apr 26, 1993  |  BioCentury | Tools & Techniques

DNAP tagging isolates key gene

DNAP tagging isolates key gene DNA Plant Technology Corp. scientists have isolated a plant gene that regulates acidity, a major determinant of color in flowers and flavor in fruit. DNAP said publication of the findings...
12:00 AM, Apr 26, 1993  |  BioCentury | Strategy

Repligen seeds a start-up

Repligen seeds a start-up Repligen Corp. has provided an undisclosed amount of seed funding for Glycan Pharmaceuticals Inc., a new company founded by three of its senior scientists. Glycan will develop small-molecule drugs targeted at...
12:00 AM, Apr 26, 1993  |  BioCentury | Politics, Policy & Law

Doing Clinton a favor

Doing Clinton a favor The industry's "SWAT" team of biotechnology executives made its first visit to Capitol Hill last week while pharmaceutical companies advanced, and sometimes argued over, proposals for restraining drug price increases. Biotechnology...
12:00 AM, Apr 26, 1993  |  BioCentury | Strategy

Athena puts profit on the horizon

Athena puts profit on the horizon Changes Athena Neurosciences Inc. made in its product portfolio last week should increase near-term revenues, save money and bring profitability by 1995, according to analysts. The return to A.H. Robins...
12:00 AM, Apr 26, 1993  |  BioCentury | Strategy

HIV club says door is open; Market choked with patches

HIV club says door is open Biotechnology companies with anti-viral HIV research programs can join the 15 U.S. and European pharmaceutical companies that will collaborate on clinical trials of combined anti-viral HIV therapies, but they...
12:00 AM, Apr 26, 1993  |  BioCentury | Regulation

Quadra Logic gets first product approval

Quadra Logic Technologies Inc. (QLTIF) received clearance from the Health Protection Branch in Canada to market its light-activated drug, Photofrin, as a treatment for recurrent superficial papillary bladder cancer. This is the company's first product...
12:00 AM, Apr 26, 1993  |  BioCentury | Regulation

Another rejection of Quayle

Policy on biotech foods Another rejection of Quayle By Kris Herbst Contributing Editor WASHINGTON - FDA Commissioner David Kessler has reassured Congress that the agency's policy for commercialization of genetically engineered food products does...
12:00 AM, Apr 19, 1993  |  BioCentury | Strategy

TSIN rethinks its ambitions

TSI Corp., suffering indigestion from an ambitious growth-oriented strategy, last week embarked on a downsizing that it hopes will be in place by the end of the year. James Sherblom resigned as chairman, president and...
12:00 AM, Apr 19, 1993  |  BioCentury | Strategy

CentoRX cost-benefit comparison

CentoRX cost-benefit comparison Trial Implied Implied Trial Implied Implied Cost incidence: number in cost to incidence: number in cost to Event to treat placebo total pop. treat CentoRx total pop. treat CABG $15,000 3.60%...

Pages